Literature DB >> 31211239

Glutamine addiction: an Achilles heel in esophageal cancers with dysregulation of CDK4/6.

Shuo Qie1, J Alan Diehl1.   

Abstract

Understanding and overcoming resistance to cyclin-dependent kinase 4/6 (CDK4/6) inhibitors will be challenging. Recent work reveals that dysregulation of F-Box Protein 4 (FBXO4)-Cyclin D1 axis leads to mitochondrial dysfunction and drives glutamine-addiction in esophageal squamous cell carcinoma. This metabolism feature makes these tumors susceptible to combined treatment with glutaminase (GLS) inhibitor and metformin even when resisting to CDK4/6 inhibitors.

Entities:  

Keywords:  CDK4/6 inhibitor; Glutamine-addiction; acquired resistance; cyclin D1; glutaminase

Year:  2019        PMID： 31211239      PMCID： PMC6548481          DOI： 10.1080/23723556.2019.1610257

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN： 2372-3556


  10 in total

Review 1.  CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought.

Authors:  Mary E Klein; Marta Kovatcheva; Lara E Davis; William D Tap; Andrew Koff
Journal:  Cancer Cell       Date:  2018-05-03       Impact factor: 31.743

2.  ErbB2 activation upregulates glutaminase 1 expression which promotes breast cancer cell proliferation.

Authors:  Shuo Qie; Clarissa Chu; Weihua Li; Chenguang Wang; Nianli Sang
Journal:  J Cell Biochem       Date:  2014-03       Impact factor: 4.429

Review 3.  Cyclin D as a therapeutic target in cancer.

Authors:  Elizabeth A Musgrove; C Elizabeth Caldon; Jane Barraclough; Andrew Stone; Robert L Sutherland
Journal:  Nat Rev Cancer       Date:  2011-07-07       Impact factor: 60.716

Review 4.  Carbon source metabolism and its regulation in cancer cells.

Authors:  Chengqian Yin; Shuo Qie; Nianli Sang
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2012       Impact factor: 1.807

5.  Loss of RBF1 changes glutamine catabolism.

Authors:  Brandon N Nicolay; Paulo A Gameiro; Katrin Tschöp; Michael Korenjak; Andreas M Heilmann; John M Asara; Gregory Stephanopoulos; Othon Iliopoulos; Nicholas J Dyson
Journal:  Genes Dev       Date:  2013-01-15       Impact factor: 11.361

Review 6.  Cyclin D1, cancer progression, and opportunities in cancer treatment.

Authors:  Shuo Qie; J Alan Diehl
Journal:  J Mol Med (Berl)       Date:  2016-10-02       Impact factor: 4.599

7.  Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis.

Authors:  Yan Xiang; Zachary E Stine; Jinsong Xia; Yunqi Lu; Roddy S O'Connor; Brian J Altman; Annie L Hsieh; Arvin M Gouw; Ajit G Thomas; Ping Gao; Linchong Sun; Libing Song; Benedict Yan; Barbara S Slusher; Jingli Zhuo; London L Ooi; Caroline G L Lee; Anthony Mancuso; Andrew S McCallion; Anne Le; Michael C Milone; Stephen Rayport; Dean W Felsher; Chi V Dang
Journal:  J Clin Invest       Date:  2015-04-27       Impact factor: 14.808

8.  Mutations in Fbx4 inhibit dimerization of the SCF(Fbx4) ligase and contribute to cyclin D1 overexpression in human cancer.

Authors:  Olena Barbash; Petia Zamfirova; Douglas I Lin; Xiangmei Chen; Ke Yang; Hiroshi Nakagawa; Fengmin Lu; Anil K Rustgi; J Alan Diehl
Journal:  Cancer Cell       Date:  2008-07-08       Impact factor: 31.743

9.  Fbxo4-mediated degradation of Fxr1 suppresses tumorigenesis in head and neck squamous cell carcinoma.

Authors:  Shuo Qie; Mrinmoyee Majumder; Katarzyna Mackiewicz; Breege V Howley; Yuri K Peterson; Philip H Howe; Viswanathan Palanisamy; J Alan Diehl
Journal:  Nat Commun       Date:  2017-11-16       Impact factor: 14.919

10.  Targeting glutamine-addiction and overcoming CDK4/6 inhibitor resistance in human esophageal squamous cell carcinoma.

Authors:  Shuo Qie; Akihiro Yoshida; Stuart Parnham; Natalia Oleinik; Gyda C Beeson; Craig C Beeson; Besim Ogretmen; Adam J Bass; Kwok-Kin Wong; Anil K Rustgi; J Alan Diehl
Journal:  Nat Commun       Date:  2019-03-21       Impact factor: 14.919
  10 in total
  3 in total

Review 1.  Cyclin D degradation by E3 ligases in cancer progression and treatment.

Authors:  Shuo Qie; J Alan Diehl
Journal:  Semin Cancer Biol       Date:  2020-01-30       Impact factor: 15.707

Review 2.  The E3 Ubiquitin Ligase Fbxo4 Functions as a Tumor Suppressor: Its Biological Importance and Therapeutic Perspectives.

Authors:  Shuo Qie
Journal:  Cancers (Basel)       Date:  2022-04-25       Impact factor: 6.575

Review 3.  Stanniocalcin 2 (STC2): a universal tumour biomarker and a potential therapeutical target.

Authors:  Shuo Qie; Nianli Sang
Journal:  J Exp Clin Cancer Res       Date:  2022-05-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.